MedTrace Logo

A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia

NCT07695597 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-07-22

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.

Conditions

  • Mixed Hyperlipidemia

Interventions

DRUG

SYH2070

SYH2070 injection, 150 mg, 300 mg, 400 mg, SC, administration duration: 24 weeks

DRUG

Placebo

Placebo, SC, administration duration: 24 weeks

Sponsors & Collaborators

  • CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2027-04-30
Completion
2027-09-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07695597 on ClinicalTrials.gov